Abstract 598TiP
Background
Lung cancer is currently the leading cause of death in cancer patients, non-small cell lung cancer (NSCLC) accounts for 80%-85% and the morbidity is increasing. About 70% of the cases have reached the advanced stage at the time of diagnosis. In some patients, the ECOG performance status (PS) score rates from 2 to 4 with worse prognosis and tolerance. Hence, Prof. Zhou's team defined the concept of "advanced severe lung cancer" in 2017. Currently, most guidelines recommend EGFR-TKIs as first-line treatment for EGFR mutation-positive (19del and L858R) patients. However, PS 2-4 patients were not included in most clinical trials. Thus, the efficacy and safety of EGFR-TKIs for PS 2-4 patients are still unknown in the real world. Aumolertinib is a third-generation EGFR-TKI independently developed in China with lower incidence of adverse events, which may be a better choice for advanced severe lung cancer patients. Thus, this study was designed to explore the efficacy and safety of aumolertinib in the first-line treatment of advanced non-small cell lung cancer patients of PS 3 with EGFR mutations. This may provide valuable hints for clinical applications.
Trial design
A total of 61 patients with EGFR mutations positive (19del and L858R) advanced non-small cell lung cancer with PS 3 will be enrolled and applying Aumolertinib 110 mg PO QD until progression. The primary endpoints are Objective Response Rate (ORR) and the duration of PS improved from 3 at baseline to 1. Secondary endpoints are progression-free survival (PFS), overall survival (OS), quality of life (QoL), disease control rate (DCR) and safety.
Clinical trial identification
NCT05826483.
Legal entity responsible for the study
The First Affiliated Hospital of Guangzhou Medical University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
591P - The utility of next generation sequencing for KRAS gene variants prevalence in cytological and tissue samples in real-world NSCLC patients: A large single institution real-world study
Presenter: Adam Pluzanski
Session: Poster Display
Resources:
Abstract
592P - Treatment patterns and outcomes in patients with advanced non-small cell lung cancer with MET exon 14 skipping alterations in China
Presenter: Hanxiao Chen
Session: Poster Display
Resources:
Abstract
593P - MET TKIs in Asian patients (pts) with MET exon 14 skipping NSCLC: A matching-adjusted indirect comparison (MAIC)
Presenter: E-e Ke
Session: Poster Display
Resources:
Abstract
594P - The treatment pattern and clinical outcome in NSCLC patients with MET alteration: A retrospective real-world analysis in China
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
595P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Presenter: Koichi Goto
Session: Poster Display
Resources:
Abstract
596P - Repotrectinib in patients (pts) from Asia and China with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial
Presenter: Ross Soo
Session: Poster Display
Resources:
Abstract
597TiP - A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC
Presenter: Sun Min Lim
Session: Poster Display
Resources:
Abstract
599TiP - A prospective study of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression (FirstMET)
Presenter: Shuting Zhan
Session: Poster Display
Resources:
Abstract
600TiP - Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC)
Presenter: Junko Tanizaki
Session: Poster Display
Resources:
Abstract
601P - Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
Presenter: Xiaohua Wu
Session: Poster Display
Resources:
Abstract